Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | PDE9A | O76083 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7316083 | 0.72 | KDM4E (0.46) | ALDH1A1KDM4EHSD17B10CFTRHPGD | |
| SCHEMBL13865774 | 0.70 | ALDH1A1 (0.46) | ALDH1A1KDM4EHSD17B10PDE7APDE7B | |
| SCHEMBL5232135 | 0.70 | PDE7A (0.60) | PDE7APDE7BPDE5AHPGD | |
| SCHEMBL13865846 | 0.68 | KHK (0.48) | ALDH1A1KDM4EHSD17B10CFTRHPGD | |
| SCHEMBL5232549 | 0.68 | PDE7A (0.69) | PDE7APDE7BHPGD | |
| SCHEMBL13865755 | 0.68 | ALDH1A1 (0.44) | ALDH1A1KDM4EHSD17B10PDE7ACFTR | |
| Hydrochloric Acid SCHEMBL4511529 | 0.68 | KHK (0.46) | ALDH1A1KDM4EHSD17B10PDE7A | |
| SCHEMBL13870387 | 0.67 | KHK (0.48) | ALDH1A1KDM4EHSD17B10KMT2ACFTR | |
| SCHEMBL13865763 | 0.67 | ALDH1A1 (0.43) | ALDH1A1KDM4EHSD17B10CFTRPDE5A | |
| SCHEMBL31194502 | 0.66 | ALDH1A1 (0.40) | ALDH1A1KDM4EHSD17B10PDE7APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160206623-A9 | Composition For Prevention of Vasoactivity in the Treatment of Blood Loss and Anemia | BLUMENSTEIN JAN (CA) | 2016-07-21 | — | — | US | claimed |
| US-20150290213-A1 | Composition For Prevention of Vasoactivity in the Treatment of Blood Loss and Anemia | BLUMENSTEIN JAN (CA) | 2015-10-15 | — | — | US | claimed |
| US-8791124-B2 | Use of phosphordiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2014-07-29 | — | — | US | claimed |
| US-20130274245-A1 | Composition For Prevention of Vasoactivity in the Treatment of Blood Loss and Anemia | BLUMENSTEIN JAN (CA) | 2013-10-17 | — | — | US | claimed |
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | UROPEP BIOTECH GBR | 2012-07-05 | — | — | US | claimed |
| US-8106061-B2 | Use of phosphodiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2012-01-31 | — | — | US | claimed |
| US-20100179152-A1 | Novel use for PDE5 inhibitors | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-1740183-B1 | NOVEL USE FOR PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2009-10-14 | — | — | EP | claimed |
| US-20070185114-A1 | Novel use for pde5 inhibitors | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| US-20050107394-A1 | for the treatment of respiratory failure in patients showing a mismatch of pulmonary ventilation and pulmonary perfusion; e.g. 3-ethyl-8-[2-(4-morpholinylmethyl)benzylamino]-2,3-dihydro-1H-imidazo[4,5-g]quinazoline-2-thione | GHOFRANI ARDESCHIR (DE) | 2005-05-19 | — | — | US | claimed |
| EP-1461022-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA Pharma AG (DE) | 2004-09-29 | — | — | EP | claimed |
| EP-0754069-B1 | TREATMENT OF PULMONARY VASOCONSTRICTION AND ASTHMA | GEN HOSPITAL CORP (US) | 2004-06-23 | — | — | EP | claimed |
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PFIZER INC | 2004-05-06 | — | — | US | claimed |
| US-20030199517-A1 | Comprises 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); for treatment of benign prostatic hyperplasia and urination disorders | WOLF-GEORG FORSSMANN | 2003-10-23 | — | — | US | claimed |
| WO-2003051346-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | claimed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | claimed |
| US-20020025969-A1 | Genign prostatic hyperolasia | ERFINDERGEMEINSCHAFT UROPEP GBR (DE) | 2002-02-28 | — | — | US | claimed |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | CAMPBELL SIMON FRASER (GB) | 2001-11-22 | — | — | US | claimed |
| EP-0793486-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016644-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | PDE5A, PDE7A, PDE12 | GRIA1 2573/4885GRIA2 3790/4885GRIA3 3981/4885 |
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE2A | GRIA1 1631/4885GRIA2 2376/4885GRIA3 1670/4885 |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE2A, PDE3B | GRIA1 2591/4885GRIA2 3675/4885GRIA3 2629/4885 |
| US-20030199517-A1 | Comprises 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); for treatment of benign prostatic hyperplasia and urination disorders | PDE12, PDE5A, QDPR | GRIA1 3265/4885GRIA2 3995/4885GRIA3 4394/4885 |
| US-20020025969-A1 | Genign prostatic hyperolasia | PDE5A, PDE3A, PDE2A | GRIA1 657/4885GRIA2 1377/4885GRIA3 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.